HPPH-Photodynamic Therapy Safe in Precancerous Barrett's

Photodynamic therapy with 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a is safe, promising

THURSDAY, Sept. 8 (HealthDay News) -- Photodynamic therapy (PDT) with 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) is safe with promising efficacy in precancerous lesions associated with Barrett's esophagus, according to a study published in the September issue of Lasers in Surgery and Medicine.

Hector R. Nava, M.D., from the Roswell Park Cancer Institute in Buffalo, N.Y., and colleagues investigated the optimal drug and light doses, and toxicity of endoscopic PDT with HPPH (HPPH-PDT) in precancerous lesions in Barrett's esophagus, and the efficacy of one-time treatment with HPPH-PDT. A total of 36 patients with biopsy-proven high grade dysplasia or early intramucosal adenocarcinomas of the esophagus participated in two non-randomized (18 patients each) dose escalation studies. In the drug dose ranging study, HPPH doses of 3 to 6 mg/m² were followed by one endoscopic fixed light dose of 150 J/cm, 48 hours after HPPH infusion. In the light dose ranging study, three light doses (150, 175, or 200 J/cm) were delivered 24 hours after HPPH administration at two doses (3 and 4 mg/m²).

The investigators found that most patients had mild to moderate chest pain requiring symptomatic treatment, and 16.6 percent of the patients experienced grade 3 or 4 adverse events. Esophageal strictures were treated by dilatation in three cases. There was no clear pattern of dose dependent toxicities. For the drug dose ranging study 3 and 4 mg/m² of HPPH were the most effective. The light dose ranging study had a one-year complete response rate of 72 percent (disappearance of high grade dysplasia and early carcinoma). A one-year complete response rate was seen in all patients treated with 3 mg/m² HPPH with 175 J/cm and 4 mg/m² HPPH with 150 J/cm.

"HPPH-PDT for precancerous lesions in Barrett's esophagus appears to be safe and showing promising efficacy," the authors write.

Two of the study authors disclosed financial relationships with the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2011 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles

Blunt Chest Trauma
Journal of Trauma Nursing, November/December 2014
Expires: 12/31/2016 CE:2 $21.95


The School Age Child with Congenital Heart Disease
MCN, The American Journal of Maternal/Child Nursing, January/February 2015
Expires: 2/28/2017 CE:2.5 $24.95


Understanding multiple myeloma
Nursing Made Incredibly Easy!, January/February 2015
Expires: 2/28/2017 CE:2 $21.95


More CE Articles

Subscribe to Recommended CE

Recommended Nursing Articles

Comprehensive Care: Looking Beyond the Presenting Problem
Journal of Christian Nursing, January/March 2015
Free access will expire on March 2, 2015.


Pain and Alzheimer dementia: A largely unrecognized problem
Nursing Made Incredibly Easy!, January/February 2015
Free access will expire on February 16, 2015.


Glycemic control in hospitalized patients
Nursing2015 Critical Care, January 2015
Free access will expire on February 16, 2015.


More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events